TruWealth Advisors’s iShares Biotechnology ETF IBB Stock Holding History

TruWealth Advisors’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,577	Closed	-$216K	–	166
2024 Q1	$216K	Hold	1,577	–	–	0.02%	156
2023 Q4	$214K	Sell	1,577 -465	-23%	-$56.7K	0.02%	144
2023 Q3	$250K	Sell	2,042 -79	-4%	-$10K	0.02%	126
2023 Q2	$269K	Sell	2,121 -1,048	-33%	-$136K	0.02%	127
2023 Q1	$409K	Hold	3,169	–	–	0.04%	97
2022 Q4	$416K	Sell	3,169 -240	-7%	-$31K	0.04%	95
2022 Q3	$399K	Sell	3,409 -696	-17%	-$86.4K	0.04%	89
2022 Q2	$483K	Sell	4,105 -202	-5%	-$24K	0.05%	78
2022 Q1	$561K	Sell	4,307 -689	-14%	-$89.8K	0.06%	70
2021 Q4	$762K	Sell	4,996 -648	-11%	-$100K	0.08%	67
2021 Q3	$913K	Sell	5,644 -202	-3%	-$34K	0.1%	63
2021 Q2	$957K	Sell	5,846 -2,566	-31%	-$395K	0.11%	62
2021 Q1	$1.27M	Sell	8,412 -979	-10%	-$155K	0.17%	54
2020 Q4	$1.42M	Buy	+9,391	New	+$1.34M	0.21%	44

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

TruWealth Advisors's IBB Position: Q2 2024 in Review

TruWealth Advisors sold out of iShares Biotechnology ETF (IBB) in Q2 2024, closing a stake of 1,577 shares — an estimated $216K sold.

TruWealth Advisors first reported a position in IBB in Q4 2020 and held it in 14 quarters. The position peaked at $1.42M in Q4 2020. 894 funds tracked by Wall St. Rank hold IBB as of Q2 2024.

TruWealth Advisors reported no remaining iShares Biotechnology ETF position as of Q2 2024 after selling out during the quarter.
TruWealth Advisors sold 1,577 iShares Biotechnology ETF shares in Q2 2024, an estimated $216K.
TruWealth Advisors first reported a position in iShares Biotechnology ETF in Q4 2020 and held it in 14 quarters.
TruWealth Advisors's iShares Biotechnology ETF position peaked at $1.42M in Q4 2020.
894 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2024.

Based on TruWealth Advisors's 13F filing for Q2 2024, filed 16 Jul 2024.